These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 9032295

  • 1. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation.
    Lebrun JJ, Vale WW.
    Mol Cell Biol; 1997 Mar; 17(3):1682-91. PubMed ID: 9032295
    [Abstract] [Full Text] [Related]

  • 2. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.
    Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W.
    Nature; 2000 Mar 23; 404(6776):411-4. PubMed ID: 10746731
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Activin and inhibin binding to the soluble extracellular domain of activin receptor II.
    Donaldson CJ, Vaughan JM, Corrigan AZ, Fischer WH, Vale WW.
    Endocrinology; 1999 Apr 23; 140(4):1760-6. PubMed ID: 10098513
    [Abstract] [Full Text] [Related]

  • 5. mRNA expression of type I and type II receptors for activin, transforming growth factor-beta, and bone morphogenetic protein in the murine erythroleukemic cell line, F5-5.fl.
    Machida H, Ogawa K, Funaba M, Mizutani T, Tsujimoto M.
    Eur J Endocrinol; 2000 Nov 23; 143(5):705-10. PubMed ID: 11078996
    [Abstract] [Full Text] [Related]

  • 6. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin.
    Cárcamo J, Weis FM, Ventura F, Wieser R, Wrana JL, Attisano L, Massagué J.
    Mol Cell Biol; 1994 Jun 23; 14(6):3810-21. PubMed ID: 8196624
    [Abstract] [Full Text] [Related]

  • 7. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism.
    Xu J, McKeehan K, Matsuzaki K, McKeehan WL.
    J Biol Chem; 1995 Mar 17; 270(11):6308-13. PubMed ID: 7890768
    [Abstract] [Full Text] [Related]

  • 8. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
    Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K.
    J Cell Biol; 1995 Jul 17; 130(1):217-26. PubMed ID: 7790373
    [Abstract] [Full Text] [Related]

  • 9. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
    Alexander JM, Bikkal HA, Zervas NT, Laws ER, Klibanski A.
    J Clin Endocrinol Metab; 1996 Feb 17; 81(2):783-90. PubMed ID: 8636304
    [Abstract] [Full Text] [Related]

  • 10. Smad7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation.
    Kitamura K, Aota Si, Sakamoto R, Yoshikawa SI, Okazaki K.
    Blood; 2000 Jun 01; 95(11):3371-9. PubMed ID: 10828018
    [Abstract] [Full Text] [Related]

  • 11. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
    Di Simone N, Crowley WF, Wang QF, Sluss PM, Schneyer AL.
    Endocrinology; 1996 Feb 01; 137(2):486-94. PubMed ID: 8593793
    [Abstract] [Full Text] [Related]

  • 12. Identification of a binding site on the type II activin receptor for activin and inhibin.
    Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W.
    J Biol Chem; 2000 Feb 04; 275(5):3206-12. PubMed ID: 10652306
    [Abstract] [Full Text] [Related]

  • 13. Molecular characterization of a type I serine-threonine kinase receptor for TGF-beta and activin in the rat pituitary tumor cell line GH3.
    Takumi T, Moustakas A, Lin HY, Lodish HF.
    Exp Cell Res; 1995 Jan 04; 216(1):208-14. PubMed ID: 7813622
    [Abstract] [Full Text] [Related]

  • 14. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
    Kaivo-Oja N, Mottershead DG, Mazerbourg S, Myllymaa S, Duprat S, Gilchrist RB, Groome NP, Hsueh AJ, Ritvos O.
    J Clin Endocrinol Metab; 2005 Jan 04; 90(1):271-8. PubMed ID: 15483083
    [Abstract] [Full Text] [Related]

  • 15. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.
    Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, Zhang X, Klibanski A.
    Mol Endocrinol; 2000 Dec 04; 14(12):2066-75. PubMed ID: 11117535
    [Abstract] [Full Text] [Related]

  • 16. Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system.
    del Re E, Sidis Y, Fabrizio DA, Lin HY, Schneyer A.
    J Biol Chem; 2004 Dec 17; 279(51):53126-35. PubMed ID: 15475360
    [Abstract] [Full Text] [Related]

  • 17. Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE).
    Choi KC, Kang SK, Nathwani PS, Cheng KW, Auersperg N, Leung PC.
    Mol Cell Endocrinol; 2001 Mar 28; 174(1-2):99-110. PubMed ID: 11306176
    [Abstract] [Full Text] [Related]

  • 18. Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors.
    Chapman SC, Bernard DJ, Jelen J, Woodruff TK.
    Mol Cell Endocrinol; 2002 Oct 31; 196(1-2):79-93. PubMed ID: 12385827
    [Abstract] [Full Text] [Related]

  • 19. Modulation of activin signal transduction by inhibin B and inhibin-binding protein (INhBP).
    Chapman SC, Woodruff TK.
    Mol Endocrinol; 2001 Apr 31; 15(4):668-79. PubMed ID: 11266516
    [Abstract] [Full Text] [Related]

  • 20. Truncated activin type II receptor inhibits erythroid differentiation in K562 cells.
    Liu F, Shao LE, Yu J.
    J Cell Biochem; 2000 Apr 31; 78(1):24-33. PubMed ID: 10797563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.